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Background
Weight gain is a major side effect of treatment with psy-
chotropic agents [1]. Besides its adverse metabolic
effects, weight gain may also impair physical functioning
and quality of life (QoL) [2]. Clinical weight manage-
ment programs are reported to improve quality of life in
obese individuals not receiving psychotropic therapy [3],
but this has not been sufficiently investigated in patients
with psychiatric disorders.
The primary objective of this study is to assess
the impact of the Greek Solutions for Wellness (SfW)
3-month program, which focuses on nutrition and
physical exercise, on QoL in patients with a psychiatric
disorder who are taking psychotropic medication and
have a weight problem. Secondarily it aims to investigate
the impact of baseline patient variables (e.g. age, sex,
diagnosis) on QoL at month 3.
Materials and methods
This 26-week prospective observational study enrolled
359 patients from outpatient settings routinely carrying
out the Greek SfW, from 23/JAN/2007 to 27/FEB/
2008. 297 of them entered the program while 62
others who declined, were used as a control group.
The QoL instrument Subjective Well-Being under
Neuroleptics (SWN), the Clinical Global Impression
(CGI) scale, weight (kg), body mass index (BMI, kg/m2)
and waist circumference (WC) (cm) were collected at
baseline, months 3 (program completion) and 6 (follow
up visit). In addition, diagnosis, disorder duration, treat-
ment regimen and demographic characteristics (age,
sex) were recorded. The proportion of patients with a
QoL improvement (any SWN increase) was estimated
together with their 95% CI in both groups at month 3.
Further, stepwise logistic regression models were fitted
to adjust the SfW effect on QoL at month 3, controlling
for baseline potential confounders and first-degree
interactions. A sensitivity analysis was conducted after
implausible WC values were found in the database.
Results
Patient characteristics were similar across both groups:
Out of 359 patients, a total of 198 (55.2%) were female,
the mean age (SD) was 40.6 years (10.9), mean weight
(SD) 92.9 kg (17.9), mean BMI (SD) 32.2 kg/m2 (5.6).
52.4% of the patients presented with schizophrenia,
30.9% with bipolar disorder and 16.7% other. The mean
illness duration was 10.6 years (SD = 8.7). Out of 353
patients still in the study at month 3, 352 were assessa-
ble in terms of SWN increase: 206 patients out of 295
in the SfW group (69.8%) (95%CI = [64.2, 75.0]) showed
QoL improvement and 33 out of 57 (57.9%) (95%CI =
[44.1, 70.9]) in the control group. After controlling for
baseline potential confounders the difference between
the two groups was ORinitial = 1.43 [0.76; 2.67]; ORsen-
sitivity = 1.44 [0.77; 2.71]. Covariates significantly asso-
ciated with an improved QoL at month 3 included a
low SWN score (ORinitial = ORsensitivity = 0.94 [0.92;
0.96] and a low CGI-S level (ORinitial = ORsensitivity =
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QoL improvement at 3 months in patients with mental
illness as well as weight problems and on psychotropics
was associated with low baseline SWN and CGI-S
scores, while the big majority of the patients following
the Greek SfW program reported an improved QoL.
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